GLPwatch
Papers (12034)
Page 21 of 201, ranked by citation count.
- Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review).
- Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.
- LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.
- The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery-a Retrospective Analysis.
- Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
- Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation.
- Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
- Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.
- Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer.
- Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction.
- COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES.
- Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
- Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review.
- Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells.
- Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
- Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
- Transformation of oligomers of lipidated peptide induced by change in pH.
- Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity.
- Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.
- Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome.
- Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series.
- Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.
- Glucagon-like peptide-1 receptor agonist use in pregnancy: a review.
- Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
- Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.
- Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
- Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
- Injectable hydrogel for sustained protein release by salt-induced association of hyaluronic acid nanogel.
- Exendin-4 Protects Against Myocardial Ischemia-Reperfusion Injury by Upregulation of SIRT1 and SIRT3 and Activation of AMPK.
- Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
- Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis.
- Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
- Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.
- Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway.
- Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review.
- A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.
- The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
- Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
- Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study.
- Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.
- Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
- Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus.
- Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.
- Semaglutide and cancer: A systematic review and meta-analysis.
- Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea.
- Semaglutide attenuates excessive exercise-induced myocardial injury through inhibiting oxidative stress and inflammation in rats.
- Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.
- Diabesity: therapeutic options.
- Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
- Evolution of exenatide as a diabetes therapeutic.
- Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors.
- Glucagon-like peptide-1 receptor action in the vasculature.
- Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.
- Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.
- Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study.
- Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
- Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3β Pathways.
- Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors.